Drug Trial Radar · NCT07618247
Single Ascending Doses (SAD) and Multiple Ascending Doses(MAD) Study of IG001119 in Healthy Adult Participants
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
96
Planned (sponsor's estimate)
Start
Jul 7, 2026
Primary completion
Apr 30, 2027
Study completion May 30, 2027
Sponsor
- Lead sponsor
- Iongen Therapeutics Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IG001119 in Healthy Participants
Conditions
- Pain
Interventions
PlaceboDrug
Tablets for oral administration.
IG001119Drug
Tablets for oral administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence and severity of adverse events (AEs)Time frame: Up to 29 days
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
CMAX
Adelaide, South Australia, Australia · Recruiting
New Zealand Clinical Research
Christchurch, Canterbury, New Zealand · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.